NCT04493359

Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19

Switch or Maintenance of Renin-Angiotensin System Inhibitors in Patients With Covid-19: A Randomized Proof of Concept Trial

• Status: Terminated
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or switch the therapy to other antihypertensive classes.

Detailed description

Patients eligible for the study, after signing informed consent will be randomized 1:1 for maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy for other classes according to a pre-specified protocol. Patients are going to be followed during hospital stay for evaluation of clinical endpoints. Also blood and urine samples will be acquired for evaluation of renin-angiotensin system activation.

Conditions

• Covid19
• Angiotensin II Receptor Antagonist Adverse Reaction

Interventions

Type	Name	Description
DRUG	Renin-angiotensin system inhibitors	switch anti-hypertensive class

Timeline

• Start date: 2020-07-25
• Primary completion: 2021-09-28
• Completion: 2021-09-28
• First posted: 2020-07-30
• Last updated: 2021-10-06

Locations

1 site across 1 country: Brazil